Development of a miniaturized 96-Transwell air–liquid interface human small airway epithelial model
Rattachement africain : de. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
In order to overcome the challenges associated with a limited number of airway epithelial cells that can be obtained from clinical sampling and their restrained capacity to divide ex vivo, miniaturization of respiratory drug discovery assays is of pivotal importance. Thus, a 96-well microplate system was developed where primary human small airway epithelial (hSAE) cells were cultured at an air-liquid interface (ALI). After four weeks of ALI culture, a pseudostratified epithelium containing basal, club, goblet and ciliated cells was produced. The 96-well ALI cultures displayed a cellular composition, ciliary beating frequency, and intercellular tight junctions similar to 24-well conditions. A novel custom-made device for 96-parallelized transepithelial electric resistance (TEER) measurements, together with dextran permeability measurements, confirmed that the 96-well culture developed a tight barrier function during ALI differentiation. 96-well hSAE cultures were responsive to transforming growth factor β1 (TGF-β1) and tumor necrosis factor α (TNF-α) in a concentration dependent manner. Thus, the miniaturized cellular model system enables the recapitulation of a physiologically responsive, differentiated small airway epithelium, and a robotic integration provides a medium throughput approach towards pharmaceutical drug discovery, for instance, in respect of fibrotic distal airway/lung diseases.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Development of a miniaturized 96-Transwell air–liquid interface human small airway epithelial model
- Date Crossref
- 03/08/2020
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Boehringer Ingelheim (Germany) pays non établi dans la noticeEntreprise
-
Boehringer Ingelheim Pharma GmbH & Co. KG Department of Drug Discovery Sciences pays non établi dans la noticeEntreprise
-
Department of Translational Medicine and Clinical Pharmacology pays non établi dans la noticeÉtablissement de santé
Boehringer Ingelheim (Germany), Department of Drug Discovery Sciences — Boehringer Ingelheim Pharma GmbH & Co. KG et Department of Translational Medicine and Clinical Pharmacology.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.